For the first time, the US Food and Drug Administration has approved a drug made from cannabis. Epidiolex treats severe forms of childhood epilepsy — but the Drug Enforcement Administration will need to reclassify this form of cannabis before the drug can be put on the market. For almost half a century, the DEA has classified cannabis as a Schedule I drug, along with heroin and LSD. (For context, cocaine and meth are Schedule II drugs.) Schedule I drugs are considered to have “no currently accepted medical use and a high potential for abuse. “ As a result, it is extremely difficult for scientists to research the substance and pharmaceutical companies aren’t allowed to use it. But now the FDA has approved Epidiolex as a medical drug. Epidiolex contains cannabidiol, or CBD — a chemical that comes from the cannabis plant but does not have psychoactive effects — and is administered as an oil. According to DEA spokesperson Melvin Patterson, the administration had been considering reclassifying CBD and “the FDA’s findings on something like Epidiolex will weigh heavily on the decision-making process. Still, there’s no update on whether the approval will change the timeline of the proposed reclassification. The DEA could also reclassify CBD, but leave cannabis itself at Schedule I. Epidiolex treats two forms of epilepsy, Dravet syndrome and Lennox-Gastaut syndrome, which rarely respond to treatment. It is manufactured by GW Pharmaceuticals and clinical trials have shown that kids taking Epidiolex had nearly 40 percent fewer seizures per month…. [Read full story]
The Verge is an ambitious multimedia effort founded in 2011 to examine how technology will change life in the future for a massive mainstream audience.
Our original editorial insight was that technology had migrated from the far fringes of the culture to the absolute center as mobile technology created a new generation of digital consumers. Now, we live in a dazzling world of screens that has ushered in revolutions in media, transportation, and science. The future is arriving faster than ever.